679P - Third-line weekly docetaxel chemotherapy in advanced gastric cancer who failed previous fluoropyrimidine and irinotecan or oxaliplatin-based chemot...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Gastric Cancer
Biological Therapy
Presenter Guk Jin Lee
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors G.J. Lee1, Y. Hong2, S.Y. Roh3
  • 1Division Of Medical Oncology, Department Of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea,, 137-701 - Seoul/KR
  • 2Division Of Oncology, Department Of Internal Medicine, Seoul St. Mary's Hospital, 137-701 - Seoul/KR
  • 3Medical Oncology, Catholic Medical Center, Seoul/KR



As yet, there is no estabilished 3rd line chemotherapy for metastatic or recurrent gastric cancer. Docetaxel showed efficacy as salvage regimen for advanced gastric cancer (AGC) in previous studies. The efficacy of docetaxel as 3-week regimen in 3rd line was modest,but grade 3-4 neutropenia was reporte to 50%. So in this monocentric study, we studied the efficacy and the safety of weekly docetaxel regimen as 3rd line chemotherapy in AGC patients.


Between January 2011 and April 2013, we retrospectively studied 39 patients who had previous therapies including fluoropyrimidine and irinotecan or oxaliplatin and who received subsequent weekly docetaxel chemotherapy. The patients received docetaxel 35 mg/m2 on day 1,8 every 3 weeks.


Median age was 60 years old (range 38-77). 37 patients had ECOG performance status (PS) 0-1 and 2 paients (5.1%) had ECOG PS 2. The response rate was 12.8% (5/39) ad the disease control rate was 48.7% (19/39). The median progression free survival (PFS) was 66 days (95% confidence inerval [CI], 47-84) and median overall survival (OS) was 147 days (95% CI, 116-238). The patients with a good response more than stable disease in 1st line therapy had longer overall survival (p = 0.019),and the patients with a good response in 2nd line therapy had longer progression free survival in third-line docetaxel chemotherapy (p = 0.029). A total of 130 cycles of chemotherapy (median 3, range 1-13) were administered and relative dose intensity was median 0.83 (range 0.49-1.00). There were hematologic toxicities including grade 3-4 neutropenia 17.9% (7/39), grade 3-4 thrombocytopenia 2.6% (1/39), and grade 3-4 anemia 12.8% (5/39). For non-hematologic toxicities, 2 patients (5.1%) had grade 3-4 infection, 2 patients (5.1%) had grade 3-4 fatigue, 1 patient (2.6%) had grade 3 diarrhea.


Comparing to 3-week regimen, 3rd line weekly docetaxel chemotherapy showed similar efficacy and a favorable toxicity profile, especially fewer hematologic toxicities. Considering that the good response group for previous chemotherapy had a benefit, it is warranted for selecting these patients for 3rd line weekly docetaxel chemotherapy.


All authors have declared no conflicts of interest.